On Friday, an analyst from William Blair maintained an Outperform rating on shares of Alignment Healthcare Inc (NASDAQ:ALHC), following the release of the final 2025 Star Ratings by the Centers for Medicare & Medicaid Services (CMS). The data, which is crucial for Medicare Advantage (MA) plans, was published after markets closed on October 10 and is seen as highly favorable for Alignment Healthcare.
The recent release of the CMS Star Ratings has been a focal point for investors, given its impact on MA-exposed stocks. Earlier volatility was observed in the sector after Humana (NYSE:HUM) announced a significant drop in Star Ratings for its major contracts, which raised concerns about potential negative outcomes for other MA plans. However, the final ratings data appears to have alleviated some of these concerns, particularly for Alignment Healthcare.
Alignment Healthcare's management had previously expressed confidence in the company's competitive position for the year 2025. This sentiment has been bolstered by the latest CMS data, which confirms the company's ability to maintain a 4-Star Rating for its principal contract, H3815. This contract is significant, representing approximately 85% of the total health plan enrollment for the company.
The analyst noted that despite the broader industry concerns, Alignment Healthcare's final Star Rating data stands out as a positive development. It not only sustains the company's current standing but also demonstrates a competitive edge in the market. This performance is particularly noteworthy in the context of the challenges faced by other players in the Medicare Advantage space.
The reaffirmation of the 4-Star Rating for Alignment Healthcare's largest contract underscores the company's successful navigation through the regulatory environment and its commitment to maintaining high-quality service for its enrollees. The analyst's continued support reflects a positive outlook for the company's future performance in the Medicare Advantage market.
In other recent news, Alignment Healthcare has experienced significant financial growth with a 47% increase in revenue and a 56% surge in health plan membership. This positive performance prompted financial firms like Baird, TD Cowen, and Stifel to raise their price targets for the company, reflecting a strong confidence in the company's growth outlook.
KeyBanc has also initiated coverage on Alignment Healthcare, assigning a Sector Weight rating while acknowledging the potential long-term growth prospects for the company.
In the midst of these developments, Alignment Healthcare has seen a reshuffle in its board structure with the resignations of board members Thomas Carella and Jeffrey Margolis. Margolis has transitioned into a consulting agreement with Alignment Healthcare's primary operating subsidiary, with these changes not attributed to any disagreements regarding company operations, policies, or practices.
These recent developments have led to an upward adjustment in year-end membership expectations by 8,000 members and a forecast of at least 20% growth in 2025. Despite these positive projections, Alignment Healthcare has stated it has no plans to enter new states in 2025, focusing instead on profitability and expanding its national footprint.
InvestingPro Insights
The latest InvestingPro data and tips provide additional context to Alignment Healthcare's position in the Medicare Advantage market. Despite the positive news regarding the company's Star Ratings, InvestingPro Tips reveal that 6 analysts have revised their earnings downwards for the upcoming period, suggesting some caution in short-term expectations.
However, the company's financial performance shows strong growth potential. InvestingPro data indicates that Alignment Healthcare's revenue grew by an impressive 47.34% in Q2 2024 compared to the same quarter last year. This robust growth aligns with the company's competitive positioning in the Medicare Advantage market, as highlighted by the maintained 4-Star Rating.
It's worth noting that while the company is currently not profitable, with an adjusted operating income of -$128.54 million over the last twelve months, investors have shown confidence in its future prospects. This is evidenced by the strong stock performance, with a 134.65% price return over the past six months and a 53.04% return over the last year.
For investors seeking a more comprehensive analysis, InvestingPro offers 10 additional tips for Alignment Healthcare, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.